Teva Seeds OTC Growth Synergies With Former Allergan Business
This article was originally published in The Pink Sheet
Executive Summary
Teva's opportunity to compete in the US OTC drug market now that the Allergan's generic nonprescription products are under its roof makes company "more excited" about the space "than we have ever been," says CEO Sigurdur Olaf Olaffson,
You may also be interested in...
Teva’s 'Key Ingredient' For Growth: Biosimilars
Teva has conducted due diligence on 36 biosimilar companies with the aim of signing a partner soon to fill a critical gap in its generics pipeline.
Heated Drug Pricing Debate Fanned By Election, Teva's Olafsson Says
'I can't wait until it's over,' Teva's Generic Medicines CEO Sigurdur Olafsson said of the US Presidential election; then the current debate around drug pricing will return to a discussion of value, he predicted.
Private Label Mucinex March Reaches Two Formulations
Perrigo starts first shipments of a 1,200mg guaifenesin/60mg DXM generic of Mucinex DM, indicated to control coughs and to break up mucus.